TrialThe Lancet. Neurology2014

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Christian Confavreux et al.PubMed ↗Publisher ↗

No numbers read from the abstract.